Anti-ROR1 recombinant monoclonal antibody and its preparation and application

By developing anti-ROR1 recombinant monoclonal antibodies, using specific ROR1 polypeptides and recombinant protein antigens, the ROR1 and ROR2 recognition problems were solved, and high specific detection of ROR1 expression was achieved, improving the accuracy of tumor diagnosis and treatment.

CN118580358BActive Publication Date: 2024-11-29NANJING UNIONWAY BIOTECHNOLOGY CO LTD +2
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411084336.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-29
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

Existing ROR1 detection methods and targeted therapy techniques are difficult to specifically identify and distinguish ROR1 from ROR2, resulting in insufficient accuracy in tumor diagnosis and treatment.

Method used

Develop an anti-ROR1 recombinant monoclonal antibody, using specific ROR1 polypeptide antigens and recombinant protein antigens as immunogens, and obtains the antibody through immune animal screening, which can specifically recognize ROR1 but not ROR2, and is used for immunohistochemistry and indirect ELISA , flow cytometry and other technologies are used to conduct detection and screening.

Benefits of technology

Achieve high specificity and high sensitivity detection of ROR1 expression, which can accurately distinguish different types of tumors and improve the diagnostic accuracy of targeted treatment, especially in distinguishing between triple-negative breast cancer, endometrial cancer, ovarian cancer and CLL. Positive expression of tumor.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118580358B_ABST
    Figure CN118580358B_ABST
Patent Text Reader

Abstract

The present application discloses an anti-ROR1 recombinant monoclonal antibody and its preparation and application, belonging to the field of biotechnology. The anti-ROR1 recombinant monoclonal antibody is obtained by immunizing New Zealand white rabbits with a mixture of the ROR1 polypeptide antigen shown in SEQ ID NO.1 and the ROR1 recombinant protein antigen shown in SEQ ID NO.2 as an immunogen, and single B cell sorting and limiting dilution are performed. The core part of the antibody includes a heavy chain variable region and a light chain variable region domain, which can identify and detect the expression of ROR1 on tumor cells with high specificity and high sensitivity, and can be applied to immunohistochemistry, immunocytochemistry, direct and indirect ELISA, immunoblotting, flow cytometry and other detection and screening fields, which is conducive to obtaining more accurate detection and evaluation results, and reducing detection costs and interference from background signals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biotechnology, and specifically relates to anti-ROR1 recombinant monoclonal antibodies and their preparation and application. Background Art

[0002] The receptor tyrosine kinase-like orphan receptor (ROR) family belongs to receptor tyrosine kinases (RTKs) and is a type I transmembrane protein tyrosine kinase. The ROR family consists of two structurally related members, ROR1 (receptor tyrosine kinase-like orphan receptor 1) and ROR2 (receptor tyrosine kinase-like orphan receptor 2). The amino acid sequence homology between ROR1 and ROR2 is 58%. The ROR family is evolutionarily conserved throughout the animal kingdom and serves as an alternative receptor and co-receptor for WNT ligands. Among them, ROR1 has the functions of regulating cell metabolism, proliferation, apoptosis, differentiation, migration, metastasis, etc. It also participates in the process of signal exchange between cells and intracellular signal transduction, and plays a key role in embryogenesis.

[0003] Existing studies have shown that in children and adults, the expression of the intact membrane-bound ROR1 is very low or almost non-existent in normal tissues, but it is highly expressed in many malignant tumor cells, such as hematological malignancies such as chronic lymphocytic leukemia (CLL), endometrial cancer, lung cancer, pancreatic cancer, breast cancer, colon cancer, ovarian cancer, etc. Therefore, ROR1 is considered to be a very potential tumor diagnostic biomarker and tumor treatment target.

[0004] Currently, many companies are developing ROR1 detection methods or anti-cancer therapies targeting ROR1, including monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T therapies and other treatment modes. Summary of the invention

[0005] 1. Purpose of the Invention

[0006] The purpose of the present application is to provide an anti-ROR1 recombinant monoclonal antibody and its preparation and use. The recombinant monoclonal antibody is obtained by screening after immunizing an animal with a mixture of the ROR1 polypeptide antigen and the ROR1 recombinant protein antigen provided in the present application as an immunogen, and can specifically recognize ROR1. After testing on different biological samples using a variety of different immunoassay techniques, it was found that the anti-ROR1 recombinant monoclonal antibody provided in the present application can well detect the expression of ROR1 on normal epithelial cells (such as pancreatic islet and gastric antral mucosal surface and foveal epithelial cells) and tumor cells. Therefore, it can be used for screening of ROR1 by immunohistochemistry, immunoblotting, indirect ELISA, immunofluorescence, flow cytometry and other techniques.

[0007] 2. Technical solution

[0008] In order to achieve the above objectives, the technical solutions adopted in this application are as follows:

[0009] As the first aspect of the present application, the present application provides a ROR1 polypeptide antigen, whose amino acid sequence is: CSNPRYPNYMFPSQGITPQGQIAGFIGPPI (SEQ ID NO.1). The ROR1 polypeptide antigen is mixed with the ROR1 recombinant protein antigen provided by the present application and used as an immunogen to immunize animals to obtain anti-ROR1 antibodies. The anti-ROR1 antibodies can specifically recognize ROR1 but not ROR2 and other proteins.

[0010] As a second aspect of the present application, the present application also provides a ROR1 recombinant protein antigen, whose amino acid sequence is: MSSHTSSTTPSGGNATTQTTSLSASPVSNLSNPRYPNYMFPSQGITPQGQIAGFIGPPIPQNQRFIPINGYPIPPGYAAFPAAHYQPTGPPRVIQHCPPPKSRSPSSASGSTSTGHVTSLPSSGSNQEANIPLLPHMSIPNHPGGMGITVFGNKSQKPYKIDSKQASLLGDANIHGHTESMISAELHHHHHH (SEQ ID NO.2). The ROR1 recombinant protein antigen is mixed with the above-mentioned ROR1 polypeptide antigen and used as an immunogen to immunize animals to obtain anti-ROR1 antibodies, which can specifically recognize ROR1 but not ROR2 and other proteins.

[0011] As the third aspect of the present application, the present application also provides the use of the above-mentioned ROR1 polypeptide antigen and ROR1 recombinant protein antigen in screening or preparing anti-ROR1 antibodies. The application is to mix the ROR1 recombinant protein antigen with the ROR1 polypeptide antigen and use them as immunogens to immunize animals to obtain anti-ROR1 antibodies. The anti-ROR1 antibodies can specifically recognize ROR1 but not ROR2 and other proteins.

[0012] As a fourth aspect of the present application, the present application also provides an anti-ROR1 recombinant monoclonal antibody or an antigen-binding fragment thereof, which can specifically bind to ROR1, and comprises three light chain CDRs: CDR-L1, CDR-L2, CDRL-3; and three heavy chain CDRs: CDR-H1, CDR-H2, CDRH-3; CDRs are defined according to Kabat numbering; the amino acid sequence of each CDR is as follows:

[0013] CDR-L1: QSSQNVYNYNRLS (SEQ ID NO. 3), or an amino acid sequence having 1 to 3 amino acid substitutions, deletions or additions thereto;

[0014] CDR-L2: YDASTLET (SEQ ID NO. 4), or an amino acid sequence having 1 to 3 amino acid substitutions, deletions or additions thereto;

[0015] CDR-L3: CLTGTYDCANADCNA (SEQ ID NO. 5), or an amino acid sequence having 1 to 3 amino acid substitutions, deletions or additions thereto;

[0016] CDR-H1: VTISSWGVS (SEQ ID NO. 6), or an amino acid sequence having 1 to 3 amino acid substitutions, deletions or additions thereto;

[0017] CDR-H2: GGMDTYGNT (SEQ ID NO. 7), or an amino acid sequence having 1 to 3 amino acid substitutions, deletions or additions thereto;

[0018] CDR-H3: GLGL (SEQ ID NO. 8), or an amino acid sequence having 1 to 3 amino acid substitutions, deletions or additions thereto.

[0019] Furthermore, the amino acid sequence of each CDR of the above-mentioned anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof is as follows:

[0020] CDR-L1: QSSQNVYNYNRLS (SEQ ID NO.3);

[0021] CDR-L2: YDASTLET (SEQ ID NO.4);

[0022] CDR-L3: CLTGTYDCANADCNA (SEQ ID NO.5);

[0023] CDR-H1: VTISSWGVS (SEQ ID NO.6);

[0024] CDR-H2: GGMDTYGNT (SEQ ID NO.7);

[0025] CDR-H3: GLGL (SEQ ID NO. 8).

[0026] Furthermore, the above-mentioned anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof, the antibody comprises a light chain variable region and a heavy chain variable region, wherein:

[0027] The light chain variable region comprises the amino acid sequence shown in SEQ ID NO.9 or SEQ ID NO.11, or an amino acid sequence having at least 90% identity thereto:

[0028] QVVAQTASPVSAAVGGTVTIKCQSSQNVYNYNRLSWFQQKSGQPPKQLIYDASTLETGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLTGTYDCANADCNA (SEQ ID NO.9, encoded by SEQ ID NO.15),

[0029] QVVAQTASPVSAAVGGTVTIKCQSSQNVYNYNRLSWFQQKSGQPPLQLIYDASTLETGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLTGTYDCANADCNA (SEQ ID NO.11, encoded by SEQ ID NO.16);

[0030] The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO.10 or SEQ ID NO.12, or an amino acid sequence having at least 90% identity thereto:

[0031] EVQCQEVEESGGGLVTPGGTLTLTCTASGVTISSWGVSWVRQTPGNGLEWIGGMDTYGNTYYASWAKRRSTITRNTNENTVTLKMTSLTVADTATYFCMRGLGL (SEQ ID NO.10, encoded by SEQ ID NO.13),

[0032] EVQCQEVEESGGGLVTPGGTLTLTCTASGVTISSWGVSWFRQAPGNGLEWIGGMDTYGNTYYASWAKRRSTITRNTNENTVTLKMTSLTVADTATYFCMRGLGL (SEQ ID NO. 12, encoded by SEQ ID NO. 14).

[0033] Furthermore, the above-mentioned anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof, the antibody comprises a light chain variable region and a heavy chain variable region, wherein:

[0034] The light chain variable region comprises the amino acid sequence shown in SEQ ID NO.9 or SEQ ID NO.11;

[0035] The heavy chain variable region includes the amino acid sequence shown in SEQ ID NO.10 or SEQ ID NO.12.

[0036] Furthermore, the above-mentioned anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof, the antibody comprises a light chain variable region and a heavy chain variable region, wherein:

[0037] The light chain variable region includes the amino acid sequence shown in SEQ ID NO.9,

[0038] The heavy chain variable region includes the amino acid sequence shown in SEQ ID NO.10.

[0039] Furthermore, the above-mentioned anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof, the antibody comprises a light chain variable region and a heavy chain variable region, wherein:

[0040] The light chain variable region includes the amino acid sequence shown in SEQ ID NO.11,

[0041] The heavy chain variable region includes the amino acid sequence shown in SEQ ID NO.12.

[0042] Furthermore, the above-mentioned anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof, the antibody comprises a light chain variable region and a heavy chain variable region, wherein:

[0043] The light chain variable region includes the amino acid sequence shown in SEQ ID NO.9,

[0044] The heavy chain variable region includes the amino acid sequence shown in SEQ ID NO.12.

[0045] Furthermore, the above-mentioned anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof, the antibody comprises a light chain variable region and a heavy chain variable region, wherein:

[0046] The light chain variable region includes the amino acid sequence shown in SEQ ID NO.11,

[0047] The heavy chain variable region includes the amino acid sequence shown in SEQ ID NO.10.

[0048] Furthermore, the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, wherein the antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab)'2 fragment, a single-chain Fv protein (scFv) or a disulfide-stabilized Fv protein (dsFv).

[0049] As the fifth aspect of the present application, the present application also provides a nucleic acid encoding the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0050] Furthermore, the nucleic acid encoding the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment comprises:

[0051] The nucleotide sequence shown in SEQ ID NO.13 is used to encode the heavy chain variable region of the above-mentioned anti-ROR1 recombinant monoclonal antibody including the amino acid sequence shown in SEQ ID NO.10:

[0052] GAAGTCCAGTGTCAGGAAGTGGAGGAGTCCGGGGGAGGCCTGGTCACGCCTGGAGGAACCCTGACACTTACTTGTACTGCTTCTGGAGTCACCATCAGTAGCTGGGGAGTGAGCTGGGTCCGACAGACTCCAGGGAACGGGCTGGAATGGATCGGAGG CATGGATACCTATGGTAATACATACTACGCGAGCTGGGCGAAAAGGCGATCCACCATCACCAGGAACACCAACGAGAACACGGTGACTCTGAAAATGACCAGTCTGACAGTCGCGGACACGGCCACCTATTTCTGTATGAGAGGACTTGGCTTG (SEQ ID NO.13); or

[0053] The nucleotide sequence shown in SEQ ID NO.14 is used to encode the heavy chain variable region of the above-mentioned anti-ROR1 recombinant monoclonal antibody including the amino acid sequence shown in SEQ ID NO.12:

[0054] GAAGTCCAGTGTCAGGAAGTGGAGGAGTCCGGGGGAGGCCTGGTCACGCCTGGAGGAACCCTGACACTCACTTGTACTGCTTCTGGAGTCACCATCAGTAGCTGGGGAGTGAGCTGGTTTCGACAGGCTCCAGGGGAACGGGCTGGAATGGATCGGAGG CATGGATACCTATGGTAATACATACTACGCGAGCTGGGCGAAAAGGCGATCCACCATCACCAGGAACACCAACGAGAACACGGTGACTCTGAAAATGACCAGTCTGACAGTCGCGGACACGGCCACCTATTTCTGTATGAGAGGACTTGGCTTG (SEQ ID NO.14); or

[0055] The nucleotide sequence shown in SEQ ID NO.15 is used to encode the light chain variable region of the above-mentioned anti-ROR1 recombinant monoclonal antibody including the amino acid sequence shown in SEQ ID NO.9:

[0056] CAAGTGGTTGCTCAGACTGCCTCGCCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAAGTGCCAGTCCAGTCAGAATGTTTATAATTACAACCGTTTATCCTGGTTTCAGCAGAAATCTGGGCAGCCTCCCAAGCAACTGATCTACGATGCA TCCACTCTGGAAACTGGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTACTACTGTCTAACTGGCACCTATGATTGTGCTAATGCTGATTGTAATGCT (SEQ ID NO.15); or

[0057] The nucleotide sequence shown in SEQ ID NO.16 is used to encode the light chain variable region of the above-mentioned anti-ROR1 recombinant monoclonal antibody including the amino acid sequence shown in SEQ ID NO.11:

[0058] CAAGTGGTTGCTCAGACTGCCTCGCCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAAGTGCCAGTCCAGTCAGAATGTTTATAATTACAACCGTTTATCCTGGTTTCAGCAGAAATCTGGGCAGCCTCCCAAGCTCCTGATCTACGATGCA TCCACTCTGGAAACTGGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTACTACTGTCTAACTGGCACCTATGATTGTGCTAATGCTGATTGTAATGCT (SEQ ID NO.16);

[0059] The above nucleic acid molecules can be combined as needed.

[0060] As the sixth aspect of the present application, the present application also provides a recombinant expression vector, which contains the above-mentioned nucleic acid encoding the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, and can express the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0061] Furthermore, the above-mentioned recombinant expression vector includes: a pcDNA3.4++ plasmid containing the above-mentioned nucleic acid encoding the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0062] As the seventh aspect of the present application, the present application also provides a recombinant expression cell, which includes the above-mentioned recombinant expression vector or the above-mentioned nucleic acid encoding the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, and can express the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0063] Furthermore, the above-mentioned recombinant expression cells include: 293 cell line or CHO cell line.

[0064] As an eighth aspect of the present application, the present application also provides the use of the above-mentioned nucleic acid encoding the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, recombinant expression vector or recombinant expression cell in the preparation of the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0065] As the ninth aspect of the present application, the present application also provides a method for preparing the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, comprising: using the above-mentioned recombinant expression vector to transfect cells to obtain recombinant expression cells, and culturing the recombinant expression cells; or directly culturing the above-mentioned recombinant expression cells; collecting and purifying the supernatant to obtain the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0066] As the tenth aspect of the present application, the present application also provides the use of the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, nucleic acid encoding the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, recombinant expression vector or recombinant expression cell or anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment preparation method in detecting ROR1, or preparing ROR1 detection equipment.

[0067] Furthermore, the above-mentioned detection of ROR1 includes full-length and / or cell surface ROR1.

[0068] Furthermore, the above-mentioned detection of ROR1 refers to the detection of ROR1 expressed on the surface of tissues or cells, so as to identify whether the tissues or cells express ROR1.

[0069] Furthermore, the above-mentioned detection of ROR1 includes any one or more of immunohistochemistry, immunocytochemistry (immunofluorescence), flow cytometry, protein immunoblotting, and enzyme-linked immunosorbent assay (ELISA) to detect ROR1, and the above-mentioned different detection techniques all rely on the binding of anti-ROR1 recombinant monoclonal antibodies or their antigen-binding fragments to ROR1.

[0070] Furthermore, the above-mentioned detection of ROR1 includes: a method for detecting the presence of ROR1 in a paraffin-embedded tissue section sample, the method comprising contacting the tissue section with the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment and detecting the specific binding of the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment to the embedded tissue by an immunohistochemical method, thereby detecting paraffin tissue sections expressing ROR1, and ROR1 is optionally full-length and / or cell surface ROR1.

[0071] Furthermore, the above-mentioned ROR1 detection device includes any one or more of a kit, an antibody coupling, an antibody chip, etc.

[0072] As the eleventh aspect of the present application, the present application also provides a kit for detecting ROR1, which includes the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment, and utilizes the binding of the anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment to ROR1 to detect ROR1. The anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment can be a primary antibody.

[0073] Furthermore, the above-mentioned kit is a flow cytometry detection kit, comprising the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0074] Furthermore, the above-mentioned kit is a flow cytometry detection kit, which also includes a flow cytometry detection reagent.

[0075] Furthermore, the above-mentioned flow cytometry detection kit also includes: fluorescently labeled secondary antibodies, PBS, bovine serum albumin, Human IgG, 7-AAD and other reagents required for flow cytometry detection.

[0076] Furthermore, the above-mentioned kit is an immunohistochemistry detection kit, comprising the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0077] Furthermore, the above-mentioned kit is an immunohistochemical detection kit, which also includes immunohistochemical detection reagents.

[0078] Furthermore, the above-mentioned immunohistochemical detection kit includes: HRP enzyme-labeled secondary antibody, EDTA repair solution, catalase blocking solution, DAB concentrate, DAB buffer, hematoxylin, blueing solution and other reagents required for immunohistochemical detection.

[0079] Furthermore, the above-mentioned kit is an immunocytochemistry detection kit, comprising the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment.

[0080] Furthermore, the above-mentioned kit is an immunocytochemical detection kit, which also includes immunocytochemical detection reagents.

[0081] Furthermore, the above-mentioned immunocytochemical detection kit also includes: rinsing solution, anhydrous methanol cell fixative, cell preservation solution, Triton X-100 cell permeabilizer, cell blocking solution, fluorescently labeled secondary antibody, anti-fluorescence quenching DAPI mounting medium and other reagents required for immunocytochemical detection.

[0082] As the twelfth aspect of the present application, the present application also provides the use of the above-mentioned kit for detecting ROR1 in detecting ROR1.

[0083] Furthermore, the above-mentioned kit for detecting ROR1 is a flow cytometry detection kit, and the application of the above-mentioned flow cytometry detection kit includes: cell recovery, FC receptor blocking, primary antibody incubation, secondary antibody incubation, 7-AAD activity staining, online data collection, etc.

[0084] Furthermore, the above-mentioned kit for detecting ROR1 is an immunohistochemistry detection kit, and the application of the above-mentioned immunohistochemistry detection kit includes: dewaxing, antigen repair, endogenous peroxidase inactivation, blocking, primary antibody incubation, secondary antibody incubation, DAB color development, counterstaining, dehydration, sealing and microscopy, etc.

[0085] Furthermore, the above-mentioned kit for detecting ROR1 is an immunocytochemistry detection kit, and the application of the above-mentioned immunocytochemistry detection kit includes: cell treatment, cell preservation, cell permeabilization, blocking, primary antibody incubation, secondary antibody incubation, sealing and microscopy, etc.

[0086] As the thirteenth aspect of the present application, the present application also provides the use of the above-mentioned anti-ROR1 recombinant monoclonal antibody or its antigen-binding fragment in the preparation of a drug for treating tumors.

[0087] Furthermore, the above tumors include hematological malignancies or solid tumors.

[0088] Furthermore, the above-mentioned tumors include one or more of chronic lymphocytic leukemia (CLL), ovarian cancer, lung adenocarcinoma, intestinal cancer, endometrial cancer, triple-negative breast cancer, pancreatic cancer and prostate cancer.

[0089] 3. Beneficial effects

[0090] Compared with the prior art, the present application has the following beneficial effects:

[0091] (1) The anti-ROR1 recombinant monoclonal antibody provided in the present application and its preparation and application, the anti-ROR1 recombinant monoclonal antibody binds to the ROR1 molecule with high specificity and high sensitivity, can specifically identify and detect the expression of ROR1 on tumor tissues and cells, and is positive for high expression when detecting ROR1. Therefore, the anti-ROR1 recombinant monoclonal antibody can be used for immunohistochemistry, indirect ELISA, antibody chip, flow cytometry, immunoblotting, immunofluorescence and other technologies to detect and screen ROR1, which is conducive to obtaining accurate evaluation and detection results.

[0092] (2) The anti-ROR1 recombinant monoclonal antibody provided in this application, due to its good specificity, no cross-reactivity with ROR2, strong positive signal and other characteristics, can more easily distinguish the positive tumors such as triple-negative breast cancer, endometrial cancer, ovarian cancer and CLL, which is beneficial to improve the accuracy of companion diagnosis of targeted therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0093] Figure 1 This is the SDS-PAGE gel running result after the preparation of ROR1 recombinant protein antigen, where: M represents Marker; R represents reducing; N represents non-reducing.

[0094] Figure 2 These are the results of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 prepared in the present application in detecting the expression of ROR1 in normal human pancreatic tissue, gastric tissue and tonsil tissue.

[0095] Figure 3 These are the results of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 of the present application in detecting the expression of ROR1 in human mantle cell lymphoma tissues, human endometrial cancer tumor tissues, and human ovarian cancer tumor tissues.

[0096] Figure 4 These are the results of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 of the present application in detecting the expression of ROR1 and ROR2 in cells overexpressing ROR1 and ROR2.

[0097] Figure 5 These are the results of the anti-ROR1 recombinant monoclonal antibody SDT-R502 of the present application in detecting the expression of ROR1 on ROR1-positive cells MD-MB-231 and ROR1-negative cells MCF-7.

[0098] Figure 6 These are the results of the anti-ROR1 recombinant monoclonal antibody SDT-R502 of the present application in detecting ROR1 expression in normal human pancreatic, ovarian cancer, lung adenocarcinoma, intestinal cancer, endometrial cancer, triple-negative breast cancer, pancreatic cancer and prostate cancer tissues.

[0099] Figure 7 These are the results of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 of the present application in detecting the expression of ROR1 on ROR1-positive cells MD-MB-231 and ROR1-negative cells MCF-7.

[0100] Figure 8 The anti-human ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 were added to ROR1-negative and -positive breast cancer cells, and then flow cytometry staining analysis was performed. The flow cytometric analysis comparison of rabbit monoclonal IgG isotype control (black), unlabeled control (cells not incubated with primary and secondary antibodies, blue), and MCF-7 (left) / MDA-MB-231 (right) cells labeled with ROR1 antibody at a dilution of 1 / 50 (1 μg, red) was obtained.

[0101] Fig. 9 These are the results of Western blotting of anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 in different cell lysates (including negative and positive cell lysates). DETAILED DESCRIPTION

[0102] The present application is further described below in conjunction with specific embodiments.

[0103] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs; the term "and / or" used herein includes any and all combinations of one or more of the associated listed items.

[0104] If the specific conditions are not specified in the examples, the experiments were carried out according to conventional conditions or the conditions recommended by the product manufacturers. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased from the market.

[0105] As used herein, the term "about" is used to provide flexibility and imprecision associated with a given term, measurement or value. The degree of flexibility for a particular variable can be easily determined by one skilled in the art.

[0106] Concentration, amount and other numerical data can be presented in range format herein.It should be understood that such range format is used only for convenience and brevity, and should be flexibly interpreted as not only including the numerical value clearly stated as the range limit, but also including all individual numerical values ​​or sub-ranges contained in the range, just as each numerical value and sub-range are clearly stated.For example, the numerical range of about 1 to about 4.5 should be interpreted as not only including the limit value of 1 to about 4.5 clearly stated, but also including individual numbers (such as 2,3,4) and sub-ranges (such as 1 to 3, 2 to 4, etc.).The same principle is applicable to the range of only narrating a numerical value, such as "less than about 4.5", which should be interpreted as including all the above-mentioned values ​​and ranges.In addition, no matter how the breadth of the described range or feature is, this interpretation should be applied.

[0107] In this application, human tissue samples are formalin-fixed and paraffin-embedded human tissue samples, all of which have been pathologically confirmed and have patient informed consent.

[0108] Example 1

[0109] This embodiment provides ROR1 polypeptide antigens and ROR1 recombinant protein antigens, including the selection of ROR1 polypeptide antigens and the selection and preparation of ROR1 recombinant protein antigens.

[0110] (1) Selection of ROR1 peptide antigen

[0111] The sequence of the ROR1 molecule was analyzed, and based on the structure of the ROR1 protein molecule on the cell membrane, antigenicity, hydrophilicity of the constituent amino acids, and secondary structure, a polypeptide fragment with the amino acid sequence: CSNPRYPNYMFPSQGITPQGQIAGFIGPPI (SEQ ID NO.1) was selected as the ROR1 polypeptide antigen. This polypeptide fragment has strong immunogenicity and high hydrophilicity, and can be distinguished from ROR2 and other proteins. The antibodies obtained using it as an immunogen are likely to specifically recognize ROR1 but not ROR2 and other proteins.

[0112] (2) Selection of ROR1 recombinant protein antigen

[0113] The recombinant protein with the amino acid sequence: MSSHTSSTTPSGGNATTQTTSLSASPVSNLSNPRYPNYMFPSQGITPQGQIAGFIGPPIPQNQRFIPINGYPIPPGYAAFPAAHYQPTGPPRVIQHCPPPKSRSPSSASGSTSTGHVTSLPSSGSNQEANIPLLPHMSIPNHPGGMGITVFGNKSQKPYKIDSKQASLLGDANIHGHTESMISAELHHHHHH (SEQ ID NO. 2) was selected as the ROR1 recombinant protein antigen.

[0114] (3) Preparation of ROR1 recombinant protein antigen

[0115] (a) Construction of recombinant expression vector

[0116] The nucleotide sequence shown in SEQ ID NO.17 is cloned into an expression vector to obtain a recombinant expression vector, wherein the nucleotide sequence shown in SEQ ID NO.17 encodes a ROR1 recombinant protein antigen, specifically comprising:

[0117] The coding gene of the ROR1 recombinant protein antigen shown in SEQ ID NO.17 was constructed between the multiple cloning sites NcoI and XhoI of the expression plasmid PET28a to obtain a recombinant expression vector named PET28a-ROR1;

[0118] (SEQ ID NO.17).

[0119] (b) Construction of recombinant engineered bacteria

[0120] The recombinant expression vector PET28a-ROR1 obtained in step (a) is transferred into a host bacterium to obtain a recombinant engineered bacterium, specifically comprising:

[0121] Take out the BL21 (DE3) competent cells from -80℃ and quickly put them in ice. After 5 minutes, wait for the bacterial block to thaw, add 100ng PET28a-ROR1 plasmid, and gently mix by tapping the bottom of the EP tube by hand. Let it stand in ice for 25 minutes.

[0122] Heat shock in a 42°C water bath for 45 seconds, quickly return to ice and let stand for 2 minutes;

[0123] Add 700 μL of sterile LB medium without antibiotics to the EP tube, mix well, and recover at 37°C, 200 rpm for 60 min;

[0124] The cells were centrifuged at 5000 rpm for 1 minute to collect the bacteria. About 100 μL of the supernatant was taken and gently pipetted to resuspend the bacteria. The culture was then inoculated into 50 mL of LB medium containing 10 μg / mL kanamycin and cultured at 37°C, 150 rpm overnight.

[0125] (c) Using recombinant engineered bacteria to induce expression of ROR1 recombinant protein antigen

[0126] Inducing the recombinant engineering bacteria to express human ROR1 recombinant protein antigen, specifically including:

[0127] At an inoculation rate of 2%, 4 mL of the overnight cultured seed solution in step (b) was transferred to a 200 mL shake flask containing LB medium containing 10 μg / mL kanamycin, and shaken in a constant temperature shaker at 37°C and 150 rpm for 2 h. IPTG (isopropyl-β-D-thiogalactoside) was added to a final concentration of 1 mmol / L, and then the expression was efficiently induced at 20°C for 14 h.

[0128] (d) Extraction and purification to obtain ROR1 recombinant protein antigen

[0129] Extracting and purifying the protein in step (c) to obtain the ROR1 recombinant protein antigen specifically includes:

[0130] The fermentation broth of the recombinant engineering bacteria with high-efficiency induced expression in step (c) was centrifuged at 12,000 rpm and 4°C for 10 minutes, the precipitated bacteria were resuspended in 50 mL of 0.2M, pH 7.4 PBS buffer, washed once, and then centrifuged at 12,000 rpm and 4°C for 10 minutes, the precipitate was resuspended in 50 mL of 0.2M, pH 7.4 PBS buffer, ultrasonicated on ice for 30 minutes, and then centrifuged at 12,000 rpm and 4°C for 15 minutes, and the supernatant was collected to obtain a protein sample;

[0131] The supernatant was filtered through a 0.45 μm filter membrane and then purified by a 5 mL nickel column. The protein sample was slowly passed through the nickel column at a flow rate of 0.5 mL / min. The impurities were washed out with 50 mL of Buffer A. The composition of Buffer A was pH 7.4, 0.2 M PBS containing 300 mM NaCl and 30 mM imidazole. The flow rate was 1 mL / min. Then, the target protein was eluted with eluent Buffer B at a flow rate of 1 mL / min. The composition of Buffer B was pH 7.4, 0.2 M PBS containing 300 mM NaCl and 300 mM imidazole.

[0132] The obtained eluate was concentrated and desalted using a 15 mL, 3 kDa ultrafiltration tube, and the buffer was replaced with pH 7.4, 0.2 M PBS. The centrifugation conditions were 4000 g, 10 minutes / time, and the ROR1 recombinant protein antigen was concentrated. Its SDS-PAGE purity was greater than 95% (such as Figure 1 as shown).

[0133] Since the amino acid sequences of ROR1 polypeptide antigen and ROR1 recombinant protein antigen are known, those skilled in the art can prepare them by biological methods or chemical synthesis methods. As an example, this embodiment provides a biological method for preparing ROR1 recombinant protein antigen.

[0134] Example 2

[0135] This example provides the screening and preparation of anti-human ROR1 recombinant rabbit monoclonal antibodies, which specifically include the following steps:

[0136] (1) Animal immunization: The ROR1 polypeptide antigen in Example 1 was coupled with KLH and mixed with the ROR1 recombinant protein antigen in Example 1 as an immunogen; the immunogen was mixed with complete Freund's adjuvant (1:1) and emulsified, and two New Zealand white rabbits were immunized by subcutaneous injection; two weeks later, the immunogen was mixed with incomplete Freund's adjuvant (1:1) and emulsified for the second and third immunizations; after the three immunizations, blood was collected and the serum titer was determined by gradient dilution by ELISA; rabbits with OD450 greater than 0.5 when the ELISA titer was 128,000 and strong membrane staining signals of part of the endometrial cancer by immunohistochemical detection were selected for splenectomy;

[0137] (2) Monoclonal preparation: Grind the spleen tissue of rabbits, and obtain a small population of B cells that can efficiently secrete monoclonal antibodies through cell sorting and limiting dilution. Screen the specific B cell population that specifically secretes monoclonal antibodies through immunohistochemistry and flow cytometry. Obtain the cDNA of the heavy and light chain gene sequences of specific B cells through RT-PCR. Construct the obtained cDNA into the pcDNA3.4++ vector through homologous recombination, transform Escherichia coli for culture, select single colonies for sequencing, and obtain nucleic acid sequences encoding different heavy and light chains. Combine different nucleic acid sequences encoding heavy and light chains in pairs, and transfect the constructed plasmid vector into the HEK293 cell line through transfection reagent, and collect the cell supernatant;

[0138] (3) Antibody sequences: The collected HEK293 cell supernatants were verified by enzyme-linked immunosorbent assay, immunohistochemistry, and flow cytometry, confirming that the antibodies expressed by the plasmids containing the following nucleic acids (positive) had a good immune reaction with the antigens. These clones were named SDT-R502 and SDT-R502-2, respectively;

[0139] The nucleic acid sequence encoding the SDT-R502 heavy chain variable region (SDT-R502-VH-DNA) is:

[0140] GAAGTCCAGTGTCAGGAAGTGGAGGAGTCCGGGGGAGGCCTGGTCACGCCTGGAGGAACCCTGACACTTACTTGTACTGCTTCTGGAGTCACCATCAGTAGCTGGGGAGTGAGCTGGGTCCGACAGACTCCAGGGAACGGGCTGGAATGGATCGGAGG CATGGATACCTATGGTAATACATACTACGCGAGCTGGGCGAAAAGGCGATCCACCATCACCAGGAACACCAACGAGAACACGGTGACTCTGAAAATGACCAGTCTGACAGTCGCGGACACGGCCACCTATTTCTGTATGAGAGGACTTGGCTTG (SEQ ID NO.13); and

[0141] The nucleic acid sequence encoding the SDT-R502-2 heavy chain variable region (SDT-R502-2-VH-DNA) is:

[0142] GAAGTCCAGTGTCAGGAAGTGGAGGAGTCCGGGGGAGGCCTGGTCACGCCTGGAGGAACCCTGACACTCACTTGTACTGCTTCTGGAGTCACCATCAGTAGCTGGGGAGTGAGCTGGTTTCGACAGGCTCCAGGGGAACGGGCTGGAATGGATCGGAGG CATGGATACCTATGGTAATACATACTACGCGAGCTGGGCGAAAAGGCGATCCACCATCACCAGGAACACCAACGAGAACACGGTGACTCTGAAAATGACCAGTCTGACAGTCGCGGACACGGCCACCTATTTCTGTATGAGAGGACTTGGCTTG (SEQ ID NO.14);

[0143] The nucleic acid sequence encoding the SDT-R502 light chain variable region (SDT-R502-VL-DNA) is:

[0144] CAAGTGGTTGCTCAGACTGCCTCGCCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAAGTGCCAGTCCAGTCAGAATGTTTATAATTACAACCGTTTATCCTGGTTTCAGCAGAAATCTGGGCAGCCTCCCAAGCAACTGATCTACGATGCA TCCACTCTGGAAACTGGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTACTACTGTCTAACTGGCACCTATGATTGTGCTAATGCTGATTGTAATGCT (SEQ ID NO.15); and

[0145] The nucleic acid sequence encoding the SDT-R502-2 light chain variable region (SDT-R502-2-VL-DNA) is:

[0146] CAAGTGGTTGCTCAGACTGCCTCGCCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAAGTGCCAGTCCAGTCAGAATGTTTATAATTACAACCGTTTATCCTGGTTTCAGCAGAAATCTGGGCAGCCTCCCAAGCTCCTGATCTACGATGCA TCCACTCTGGAAACTGGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTACTACTGTCTAACTGGCACCTATGATTGTGCTAATGCTGATTGTAATGCT (SEQ ID NO.16).

[0147] According to the above nucleic acid sequence, the amino acid sequences of the heavy chain variable region and light chain variable region of the corresponding antibody are obtained:

[0148] The amino acid sequence of the SDT-R502 heavy chain variable region (SDT-R502-VH) is:

[0149] AND

[0150] The amino acid sequence of the SDT-R502-2 heavy chain variable region (SDT-R502-2-VH) is:

[0151] EVQCQEVEESGGGLVTPGGTLTLTCTASGVTISSWGVSWFRQAPGNGLEWIGGMDTYGNTYYASWAKRRSTITRNTNENTVTLKMTSLTVADTATYFCMRGLGL (SEQ ID NO.12, encoded by SEQ ID NO.14);

[0152] The amino acid sequence of the SDT-R502 light chain variable region (SDT-R502-VL) is:

[0153] QVVAQTASPVSAAVGGTVTIKCQSSQNVYNYNRLSWFQQKSGQPPKQLIYDASTLETGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLTGTYDCANADCNA (SEQ ID NO.9, encoded by SEQ ID NO.15); and

[0154] The amino acid sequence of the SDT-R502-2 light chain variable region (SDT-R502-2-VL) is:

[0155] QVVAQTASPVSAAVGGTVTIKCQSSQNVYNYNRLSWFQQKSGQPPLQLIYDASTLETGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLTGTYDCANADCNA (SEQ ID NO. 11, encoded by SEQ ID NO. 16).

[0156] The above heavy and light chains were analyzed. Antibodies SDT-R502 and SDT-R502-2 contained six common complementary determining regions (CDRs), three light chain CDRs: CDR-L1, CDR-L2, CDRL-3; and three heavy chain CDRs: CDR-H1, CDR-H2, CDRH-3, and their amino acid sequences are as follows:

[0157] CDR-L1: QSSQNVYNYNRLS (SEQ ID NO.3);

[0158] CDR-L2: YDASTLET (SEQ ID NO.4);

[0159] CDR-L3: CLTGTYDCANADCNA (SEQ ID NO.5);

[0160] CDR-H1: VTISSWGVS (SEQ ID NO.6);

[0161] CDR-H2: GGMDTYGNT (SEQ ID NO.7);

[0162] CDR-H3: GLGL (SEQ ID NO. 8).

[0163] In the embodiment, a large number of cells are transfected with the confirmed positive expression vector, and after continued culture for 3 to 5 days, the cell suspension is collected, the supernatant is taken after centrifugation, and the cell supernatant is purified by Protein A column affinity chromatography to obtain a recombinant monoclonal antibody against human ROR1 with a purity greater than 95%.

[0164] Example 3

[0165] This example provides the use of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 screened by the present invention in detecting ROR1 protein molecules. In this example, the detection method is an immunohistochemical method (manual), and the secondary antibody used is Anti-Rabbit and Mouse HRP-DAB IHC detection kit (Stat, catalog number: S0C1001), which specifically includes:

[0166] Baking slices: 15 normal tissue slices (1 each of liver, kidney, spleen, brain, testis, stomach, colon, myocardium, skeletal muscle, placenta, prostate, lung and pancreas tissues, 2 tonsil tissues), 25 cancer tissue slices (1 each of breast cancer, hepatocellular carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, cervical cancer, colon cancer, renal clear cell carcinoma, thyroid cancer, gastric cancer, pancreatic cancer, bladder cancer, prostate cancer and mantle cell lymphoma, 2 endometrial cancers, 10 ovarian cancers), CHO cell line slices overexpressing ROR1 and CHO cell line slices overexpressing ROR2 were placed in a drying oven and baked at 63℃~65℃ for about 1 hour;

[0167] Dewaxing and hydration: The sections were placed in a) xylene twice, 7 minutes each time; b) 100% alcohol twice, 5 minutes each time; c) 90% alcohol twice, 5 minutes; d) 75% alcohol once, 3 minutes; e) 50% alcohol once, 3 minutes; after that, the sections were taken out and rinsed with distilled water three times, 5 minutes each time; all the above operations were completed in a fume hood;

[0168] Antigen repair: Place the sections in a staining box containing sodium citrate buffer or EDTA repair solution, add 2 L of distilled water to the antigen repair pot, and place the staining box in a pressure cooker for high temperature and high pressure repair. After the pressure cooker starts to release gas, close the outlet valve and continue for 40 minutes; then stop heating, open the lid, take out the inner pot, and cool it naturally; rinse with distilled water, and wash 3 times with 1×PBS, 3 minutes each time;

[0169] Block endogenous peroxidase: Place the sections after antigen retrieval in 3% H2O2 solution for 10 minutes (operate in a fume hood), then wash three times with 1× PBS, 5 minutes each time;

[0170] Nonspecific antigens were blocked with 5% BSA + 10% goat serum (PBST configuration) at room temperature for 30 minutes;

[0171] Addition of primary antibody: After blocking, knock off the blocking solution on the slide, add 100-fold diluted primary antibody (i.e., antibody SDT-R502, SDT-R502-2) (antibody concentration 0.5 mg / mL), 80 μL per well, adjust appropriately according to the size of the circle, put the slide into a humidified box, and let it stand at 37°C for 1 hour;

[0172] Addition of secondary antibody working solution: The next morning, take out the wet box and let it stand at room temperature for 10 minutes; rinse with 1×PBST 3 times, 5 minutes each time; add secondary antibody, incubate at room temperature for 30 minutes, and wash with PBST 3 times, 5 minutes each time;

[0173] DAB color development configuration: Calculated based on 100 μL per well, 6 mL is required, that is, 6 drops of color development solution are added to 6 mL of color development buffer; add freshly prepared color development solution to each piece, and color development takes 1 to 2 minutes. You can observe with the naked eye until brownish yellow appears. When the time is up, rinse directly with tap water to stop color development;

[0174] Restain with hematoxylin for 2-5 minutes; rinse with distilled water for 5 minutes, decolorize and blue in PBS for 30 seconds, and rinse with distilled water for 5 minutes;

[0175] Dehydration of sections: Dehydrate and dry in graded alcohols: a) 50% alcohol, 5 minutes; b) 75% alcohol, 5 minutes; c) 90% alcohol, 5 minutes; d) 100% alcohol 3 times, 5 minutes each time; e) xylene 2 times, 5 minutes each time;

[0176] Sealing: Add 50-100 μL of neutral gum to each slide, then slowly add a coverslip;

[0177] The sealed slides were dried overnight and observed under a microscope the next day and scanned with a tissue slicer to obtain the immunohistochemical results.

[0178] Result analysis:

[0179] Figure 2 The results of immunohistochemical detection of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 prepared in the present application on normal pancreatic tissue, gastric tissue and tonsil tissue showed strong staining on the surface of the gastric antral mucosa and the foveal epithelial cells, medium to low intensity staining on the islet cells, and contamination in the tonsil tissue, liver tissue, striated muscle, kidney tissue, etc. (except tonsil tissue not shown), indicating that ROR1 is only expressed in some normal human tissues, which is consistent with the existing research results, and also verifies its specificity for detecting ROR1.

[0180] Figure 3 The results of immunohistochemical detection of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 prepared in the present application on human mantle cell lymphoma tissues, human endometrial cancer tissues and human ovarian cancer tissues showed that strong staining was also shown in mantle cell lymphoma and endometrial cancer.

[0181] Figure 4 The results of immunohistochemical detection of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 prepared in the present application on overexpressing cells showed that the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 of the present application specifically recognized ROR1 and had no cross-reaction with ROR2 overexpressing cells.

[0182] Example 4

[0183] This example provides the use of the anti-ROR1 recombinant monoclonal antibody SDT-R502 screened by the present invention in detecting ROR1 protein molecules. The detection method is an immunohistochemistry method (on the machine), and the secondary antibody used is Bond Polymer RefineDetection (Cat. No.: DS9800), which specifically includes:

[0184] Baking: normal human pancreas slices, 21 tumor tissues (3 cases each of ovarian cancer, lung adenocarcinoma, intestinal cancer, endometrial cancer, triple-negative breast cancer, pancreatic cancer and prostate cancer), MDA-MB-231 cell line slices and MCF-7 cell line slices were baked in a drying oven at 63℃~65℃ for about 1 hour;

[0185] Dewaxing and hydration: (All operations are automatically completed in Leica BondRx) Slice with 150 μL Bond Dewax Solution (Cat. No.: AR9222), incubate at 72°C for 30 seconds, then rinse twice with 150 μL Bond Dewax Solution; rinse three times at room temperature with 150 μL 100% alcohol; rinse three times at room temperature with 150 μL Bond Wash Solution (Cat. No.: AR9590);

[0186] Antigen retrieval: add 150 μL Bond ER Solution 1 (Cat. No. AR9961) to the sections, rinse twice at room temperature, incubate at 100°C for 20 minutes with 150 μL Bond ER Solution 1, rinse once at room temperature with 150 μL Bond ER Solution 1, rinse four times at room temperature with 150 μL Bond Wash Solution, add 150 μL Bond Wash Solution, and incubate at room temperature for 30 seconds.

[0187] Block endogenous peroxidase: add 150 μL Peroxide Block solution and incubate at room temperature for 10 minutes; rinse three times with 150 μL Bond Wash Solution at room temperature;

[0188] Primary antibody incubation: add 150 μL diluted ROR1 antibody solution (1:100 dilution) and incubate at room temperature for 60 minutes; rinse 3 times with 150 μL Bond Wash Solution at room temperature; then add 150 μL Bond Wash Solution and incubate at room temperature for 2 minutes, repeat 3 times;

[0189] Secondary antibody incubation: add 150 μL of diluted Polymer solution and incubate at room temperature for 8 minutes; add 150 μL of Bond Wash Solution and incubate at room temperature for 2 minutes, repeat twice, and then rinse once with 150 μL of pure water;

[0190] DAB color development: add 150 μL Mixed DAB Refine solution and incubate at room temperature for 10 minutes; rinse three times with 150 μL pure water;

[0191] Hematoxylin counterstaining: add 150 μL of Hematoxylin solution and incubate at room temperature for 5 minutes; rinse once with 150 μL of pure water; rinse once with 150 μL of Bond Wash Solution; then rinse once with 150 μL of pure water;

[0192] Dehydration of sections: gradient alcohol dehydration and drying: a) 70% alcohol, 3 minutes; b) 100% alcohol twice, 3 minutes each time; c) xylene 3 times, 3 minutes each time;

[0193] Sealing: Add 50-100 μL of neutral gum to each slide, then slowly add a coverslip;

[0194] The sealed slides were dried overnight and observed under a microscope the next day and immunohistochemical results were obtained using tissue sections.

[0195] Result analysis:

[0196] The results of the anti-ROR1 recombinant monoclonal antibody SDT-R502 in the present application in detecting ROR1 expression in ROR1 positive cells MD-MB-231 and ROR1 negative cells MCF-7 are as follows: Figure 5 As shown, a relatively obvious membrane positive signal was detected in the MDA-MB-231 cell line; there was no positive expression in the negative cell MCF-7, which reflects that the anti-ROR1 recombinant monoclonal antibody SDT-R502 of the present application specifically recognizes ROR1.

[0197] The results of the anti-ROR1 recombinant monoclonal antibody SDT-R502 of the present application in detecting ROR1 expression in normal human pancreatic, ovarian cancer, lung adenocarcinoma, intestinal cancer, endometrial cancer, triple-negative breast cancer, pancreatic cancer and prostate cancer tissues are as follows Figure 6 As shown, normal human pancreatic islet cells showed low to medium intensity staining; varying degrees of positive expression were detected in ovarian cancer, lung adenocarcinoma, intestinal cancer, endometrial cancer, triple-negative breast cancer, pancreatic cancer, and prostate cancer.

[0198] Example 5

[0199] This example provides the use of the anti-human ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 screened by the present invention in detecting ROR1 protein molecules. The detection method is immunocytochemistry, specifically including:

[0200] Take out the fixed cell suspension (ROR1 positive cells MD-MB-231 and ROR1 negative cells MCF-7), draw circles on the slide with an immunohistochemistry pen, add 10-15 μL of cell suspension to each circle, spread the suspension evenly with a pipette tip, and dry at 37°C for 20 minutes;

[0201] The cell preservation solution was discarded, and 500 μL 1× PBS was added to each well, and the cells were rinsed at room temperature for 5 minutes. Then, 200 μL 0.1% Triton X-100 was added to each well, and the cells were permeabilized at room temperature for 5 minutes. After the permeabilization was completed, 500 μL 1× PBS was added to each well, and the cells were washed twice, each time for 5 minutes.

[0202] Add 200 μL of blocking solution to each well and block for 1 h at room temperature;

[0203] Add 200 μL of primary antibody diluted 50 times (antibody concentration 0.5 mg / mL) to each well and incubate overnight at 2-8°C;

[0204] After the primary antibody incubation, bring it to room temperature for 30 minutes, then add 500 μL of rinsing solution (PBST) and wash three times at room temperature for 5 minutes each time;

[0205] The washing solution was discarded, and 200 μL of fluorescently labeled secondary antibody (Stat, Catalog No.: S0B4004, 1:1000 dilution, dissolved in 1% BSA) was added to each well, and incubated at room temperature in the dark for 45 minutes; after the secondary antibody incubation, 500 μL of rinsing solution (PBST) was added to each well and washed three times at room temperature, each time for 5 minutes;

[0206] Add mounting medium to the slide (for a 10 mm diameter slide, it is recommended to add 5 μL of mounting medium to each slide). Hold the slide with tweezers, with the cells facing down, and cover it with the mounting medium from one side to avoid the formation of bubbles. Store at 4°C or -20°C away from light. Read the slide and take pictures under a confocal fluorescence microscope.

[0207] Result analysis:

[0208] The results of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 in the present application in detecting ROR1 expression in ROR1 positive cells MD-MB-231 and ROR1 negative cells MCF-7 are as follows: Figure 7 As shown, there was strong positive fluorescent staining on the positive cell MD-MB-231, but no fluorescent staining on the negative cell MCF-7.

[0209] Example 6

[0210] This example provides the use of the anti-human ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 screened by the present invention in detecting ROR1 protein molecules. The detection method is flow cytometry, specifically including:

[0211] After the cells (ROR1-positive cells MD-MB-231 and ROR1-negative cells MCF-7) were treated before recovery, the cell activity of all cell batches (except the induced treatment group and transfected cell samples) was counted using trypan blue if necessary;

[0212] The activity of cells should be greater than 90%. Cells were plated at 5×10 5 ~1×10 6 The cells were aliquoted into 96-well plates, centrifuged at 200 g for 3 min at 4°C, and the supernatant was discarded;

[0213] Add 100 µL of blocking solution (10% goat serum) to each well and mix thoroughly by pipetting;

[0214] Incubate on ice for 60 minutes. During the incubation, dilute the primary antibody with cleaning solution and store in a refrigerator (2-8°C) until use.

[0215] Centrifuge for 3 minutes, discard the supernatant, add 100 µL of diluted primary antibody, mix thoroughly by pipetting, incubate on ice for 30 minutes, wash and centrifuge 3 times;

[0216] Add 100 µL of diluted A488-labeled goat anti-rabbit secondary antibody, mix thoroughly by pipetting, place on ice, incubate in the dark for 30 minutes, and then wash 3 times;

[0217] Add 200 µL of 7-AAD premix to each well and resuspend. Incubate on ice (or 2~8ºC) in the dark for 5 minutes before loading.

[0218] Result analysis:

[0219] The results of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 in the present application in detecting ROR1 expression in ROR1 positive cells MD-MB-231 and ROR1 negative cells MCF-7 are as follows: Figure 8 As shown, the anti-human ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 had strong signals in the cultured positive cells MDA-MB-231, but no signals in the rabbit monoclonal IgG isotype control and the unlabeled control (cells not incubated with the primary and secondary antibodies) as well as the negative cells MCF-7.

[0220] Example 7

[0221] This example provides the use of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 screened by the present invention in detecting ROR1 protein molecules. The detection method is protein immunoblotting, specifically including:

[0222] Carefully cut the corresponding membrane with a knife, put a marker on the membrane, and mark the project number, molecular weight and other information; wet the cut membrane with 1×TBST, pour off the TBST, add 5% skim milk powder / TBS solution, and incubate on a shaker for 1 hour at a shaker speed of 35-50 r / min;

[0223] During the blocking process, prepare the antibodies to be tested and the positive control, dilute the antibodies 500 times (antibody concentration 0.5 mg / mL); the incubation volume of the small culture dish is 10 mL, the incubation volume of the QC antibody incubation box is 5 mL, and the incubation volume of the cutting board is 2 mL; shake the diluted antibodies in the incubation box and the cutting board on a shaker for 5 minutes, and the shaker speed is 35-50 r / min;

[0224] After blocking is completed, the blocked membrane surface is dried and placed in the corresponding primary antibody, and incubated on a shaker for 1 h at a speed of 35-50 r / min.

[0225] After the primary antibody incubation is completed, rinse three times with TBST, and then rinse three times on a shaker at a speed of 85-100 r / min, each time for 10 minutes; during the primary antibody washing process, the secondary antibody can be prepared; the prepared secondary antibody is placed on a shaker and shaken for 5-10 minutes at a speed of 35-50 r / min;

[0226] Pour off the TBST washing solution from the membrane after washing the primary antibody, add the secondary antibody (Stat, Catalog No.: S0B4002, Product Name: Peroxidase-conjugated AffiniPure Goat anti-rabbit IgG (H+L), HRP (GPRB110903H). 1:10,000 dilution), and incubate on a shaker for 1 h at a shaking speed of 35-50 r / min;

[0227] Wash the secondary antibody, rinse three times with 1×TBST, and then wash three times with 1×TBST, each time for 10 minutes, with a shaker speed of 85-100 r / min;

[0228] Preparation before exposure: During the washing of the secondary antibody, take the substrate (Immobilon Western Chemiluminescent HRP Substrate, Millipore, catalog number WBKLS0500) out of the refrigerator in advance; turn on the power of the chemical imaging system and pre-cool the machine; mix the liquid A in the substrate packaging box with the substrate liquid B in a ratio of 1:1, mix thoroughly, and return to room temperature; add about 1.5 mL of substrate mixture to each membrane. Different types of substrates have corresponding incubation times. Choose the appropriate incubation time according to the instructions; then blot the excess substrate with absorbent paper and prepare for exposure with the chemical imaging system;

[0229] Imaging: Place the membrane to be tested on the sample platform, close the darkroom door, open the exposure acquisition program, select the appropriate shooting distance, photo mode, set the exposure time, open the white light imaging mode, and save the image.

[0230] Result analysis:

[0231] The results are as follows Fig. 9 As shown, the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 have strong target bands in the ROR1-positive cell lysates of MDA-MB-231, PANC1, HEK293 and A549, while MCF-7 and K562 are ROR1-negative cells and do not express ROR1, so there are no target bands in the cell lysates of MCF7 and K562.

[0232] Example 8

[0233] This example provides the use of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 screened by the present invention in detecting ROR1 protein molecules. The detection method is enzyme-linked immunosorbent assay, which specifically includes:

[0234] Take out the corresponding antigen (ROR1 polypeptide antigen, ROR2 protein) from the freezer, pipette 0.5 μg / mL of antigen into the coating buffer, and mix well with a vortex mixer; add 50 μL / well of the prepared coating buffer to the marked 96-well ELISA plate, gently shake the plate to make the coating buffer cover the bottom of the well, stick a self-adhesive sticker on the top 96-well ELISA plate, and place it in a refrigerator at 2-8°C overnight;

[0235] Blocking: Add 60 µL of 1% BSA / TBS to each well and block at room temperature for 45 minutes;

[0236] Wash the plate: shake off the blocking solution, wash once with 1×PBST 200 µL / well, and dry;

[0237] Add primary antibody: dilute the primary antibody 1000 times (primary antibody concentration 0.5 mg / mL) and add 50 μL / well, incubate at 37°C for 1 hour;

[0238] Washing: shake off the primary antibody, wash three times with 1×PBST 200 μL / well, and dry;

[0239] Secondary antibody: GAR-HRP (Stat, Cat. No. S0B4002) diluted 1:8000 with 1% BSA / TBS, mixed with a vortex mixer; 50 μL / well, incubated at 37°C for 40 minutes;

[0240] Washing: shake off the secondary antibody, wash three times with 1×PBST 200 μL / well, and dry;

[0241] Color development: Add 50 μL TMB substrate to each well, develop at room temperature in the dark for 5 minutes, and stop the color development if the positive control is normal; after adding the substrate, adjust the ELISA plate so that the plate with the substrate added first is on the top; ensure that the plate with the color development solution added first stops first;

[0242] Termination: Add 50 μL of 4.9% phosphoric acid to each well in the color development order to terminate the reaction.

[0243] Reading: Read on a microplate reader at OD450nm, and read the plate within 15 minutes after termination.

[0244] Result analysis:

[0245] The titer test results of the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 at 6 gradient concentrations using polypeptide antigens and ROR2 proteins are shown in Table 1. The results show that the anti-ROR1 recombinant monoclonal antibodies SDT-R502 and SDT-R502-2 only have immune reactions with ROR1 polypeptide antigens, but not with ROR2 proteins.

[0246] Table 1

[0247]

[0248] In summary, SDT-R502 and SDT-R502-2 can fully meet the needs of companion diagnostics for anti-ROR1 monoclonal antibodies and can provide accurate detection services for the use of targeted drugs.

[0249] It is understandable that those skilled in the art can make equivalent substitutions or changes based on the technical solution and concept of the present invention, and all these changes or substitutions should fall within the protection scope of the claims attached to the present invention.

Claims

1. An anti-ROR1 recombinant monoclonal antibody or an antigen-binding fragment thereof, characterized in that: It can specifically bind to ROR1 and contains 3 light chain CDRs: CDR-L1, CDR-L2, CDRL-3; and 3 heavy chain CDRs: CDR-H1, CDR-H2, CDRH-3; CDRs are defined according to Kabat numbering; the amino acid sequence of each CDR is as follows: CDR-L1: QSSQNVYNYNRLS (SEQ ID NO.3); CDR-L2: YDASTLET (SEQ ID NO.4); CDR-L3: CLTGTYDCANADCNA (SEQ ID NO.5); CDR-H1: VTISSWGVS (SEQ ID NO.6); CDR-H2: GGMDTYGNT (SEQ ID NO.7); CDR-H3: GLGL (SEQ ID NO. 8).

2. The anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that: Said The light chain variable region comprises the amino acid sequence shown in SEQ ID NO.9, and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO.10; or The light chain variable region includes the amino acid sequence shown in SEQ ID NO.11, and the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO.

12.

3. The anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that: The antigen-binding fragment is a Fab fragment, a Fab' fragment, a F(ab)'2 fragment, a single-chain Fv protein or a disulfide-stabilized Fv protein.

4. A nucleic acid, characterized in that The nucleic acid encodes the anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.

5. The nucleic acid according to claim 4, characterized in that The nucleotide sequence of the nucleic acid encoding the light chain variable region of the amino acid sequence shown in SEQ ID NO.9 is shown in SEQ ID NO.15, and the nucleotide sequence of the nucleic acid encoding the heavy chain variable region of the amino acid sequence shown in SEQ ID NO.10 is shown in SEQ ID NO.13; or The nucleotide sequence of the nucleic acid encoding the light chain variable region of the amino acid sequence shown in SEQ ID NO.11 is shown in SEQ ID NO.16, and the nucleotide sequence of the nucleic acid encoding the heavy chain variable region of the amino acid sequence shown in SEQ ID NO.12 is shown in SEQ ID NO.

14.

6. A recombinant expression vector, characterized in that: The recombinant expression vector contains the nucleic acid according to claim 4 or 5, and expresses an anti-ROR1 recombinant monoclonal antibody or an antigen-binding fragment thereof.

7. A recombinant expression cell, characterized in that: The recombinant expression cell comprises the recombinant expression vector according to claim 6, or the nucleic acid according to claim 4 or 5.

8. Use of the nucleic acid according to claim 4 or 5, or the recombinant expression vector according to claim 6, or the recombinant expression cell according to claim 7 in preparing an anti-ROR1 recombinant monoclonal antibody or an antigen-binding fragment thereof.

9. The method for preparing the anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, characterized in that: The method comprises: Transfecting cells with the recombinant expression vector of claim 6 to obtain recombinant expression cells, and culturing the recombinant expression cells; or directly culturing the recombinant expression cells of claim 7; The supernatant is then collected and purified to obtain an anti-ROR1 recombinant monoclonal antibody or an antigen-binding fragment thereof.

10. Use of the anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, or the nucleic acid according to claim 4 or 5, or the recombinant expression vector according to claim 6, or the recombinant expression cell according to claim 7 in detecting ROR1 or preparing a device for detecting ROR1.

11. The use according to claim 10, characterized in that: The detection of ROR1 includes any one or more of immunohistochemistry, immunofluorescence, flow cytometry, protein immunoblotting, and enzyme-linked immunosorbent assay.

12. A kit for detecting ROR1, characterized in that: The kit comprises the anti-ROR1 recombinant monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.

13. A kit for detecting ROR1 according to claim 12, characterized in that: The kit includes a flow cytometry detection kit, an immunocytochemistry detection kit or an immunohistochemistry detection kit.

Citation Information

Patent Citations

  • Antibodies against ROR1 and uses thereof

    CN103429618A

  • Antibody-drug conjugate comprising antibody against human ROR1 and use for same

    CN112439075A

  • ROR1 antibody or antigen binding fragment thereof

    CN114539411A

  • Anti-human ROR1 antibody, gene and application thereof

    CN116731178A